ResearcherChinese University of Hong KongNo recent work listed
Gary Tse
Matched on ORCID iD 0000-0001-5510-1253; OpenAlex author ID A5043075532. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 3 papers
Papers 5
- Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4… Last author DOI 10.1016/j.deman.2022.100115↗
- Incidence of pancreatic cancer in angiotensin-converting enzyme inhibitors (ACEIs) versus angiotensin receptor blockers (ARBs): a population-based cohort study Co-author DOI 10.1101/2022.07.26.22278092↗
- Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study. Co-author DOI 10.1210/jendso/bvac138↗
- Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset. Co-author DOI 10.1016/j.semcancer.2018.04.004↗
- Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Co-author DOI 10.1186/1748-717x-8-44↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sharen Lee · 3 shared papers, 2022 · strength 0.42
- Paper Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors … DOI 10.1016/j.deman.2022.100115↗
- Paper Incidence of pancreatic cancer in angiotensin-converting enzyme inhibitors (ACEIs) versus angiotensin receptor blockers… DOI 10.1101/2022.07.26.22278092↗
- Paper Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study. DOI 10.1210/jendso/bvac138↗
- Bernard M.Y. Cheung · 2 shared papers, 2022 · strength 0.28
- Paper Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors … DOI 10.1016/j.deman.2022.100115↗
- Paper Incidence of pancreatic cancer in angiotensin-converting enzyme inhibitors (ACEIs) versus angiotensin receptor blockers… DOI 10.1101/2022.07.26.22278092↗
- Edward Christopher Dee · 2 shared papers, 2022 · strength 0.28
- Paper Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors … DOI 10.1016/j.deman.2022.100115↗
- Paper Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study. DOI 10.1210/jendso/bvac138↗
- Oscar Hou In Chou · 2 shared papers, 2022 · strength 0.28
- Paper Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors … DOI 10.1016/j.deman.2022.100115↗
- Paper Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study. DOI 10.1210/jendso/bvac138↗
- Raymond Ngai Chiu Chan · 1 shared paper, 2022 · strength 0.14
- Lin Zhang · 1 shared paper, 2019 · strength 0.09
- Jeffery Ho · 1 shared paper, 2019 · strength 0.09
- William Ka Kei Wu · 1 shared paper, 2019 · strength 0.09
- Marie Kate Gurka · 1 shared paper, 2013 · strength 0.03
- Colin Johnson · 1 shared paper, 2013 · strength 0.03
- Reena C. Jha · 1 shared paper, 2013 · strength 0.03
- John Lindsay Marshall · 1 shared paper, 2013 · strength 0.03
- Michael Jon Pishvaian · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.